Sara Donati, MD

Articles

New Combinations With Epirubicin in Advanced Breast Cancer

Pierfranco Conte, MD;Alessandra Gennari, MD;Elisabetta Landucci, MD;Valentina Guarneri, MD;Sara Donati, MD;Barbara Salvadori, MD;Carmelo Bengala, MD

May 1st 2001

Several trials have shown that anthracyclines and taxanes can be combined to achieve response rates ranging from 70% to 90%, with complete responses ranging from 19% to 41%. In an attempt to increase the activity while

Epirubicin/Taxane Combinations in Breast Cancer: Experience From Several Italian Trials

Pierfranco Conte, MD;Alessandra Gennari, MD;Valentina Guarneri, MD;Elisabetta Landucci, MD;Sara Donati, MD;Barbara Salvadori, MD;Carmelo Bengala, MD;Editta Baldini, MD

May 1st 2001

Doxorubicin/paclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity. A phase I/II trial replacing

Gemcitabine/Epirubicin/Paclitaxel Trials in Advanced Breast Cancer

Pierfranco Conte, MD;Barbara Salvadori, MD;Sara Donati, MD;Alessandra Gennari, MD;Gian Luigi Cetto, MD;Annamaria Molino, MD;Lucio CrinÒ, MD;Francesca Mazzoni, MD;Enzo Galligioni, MD;Maurizio Mansutti, MD

February 1st 2001

Numerous trials have shown that the pharmacokinetic interferences of epirubicin (Ellence)/paclitaxel (Taxol) combinations produce less pharmacodynamic effect than doxorubicin/paclitaxel regimens. Paclitaxel is more easily